MktsMarkets

Aclaris Therapeutics, Inc.
NASDAQ: ACRSKey statistics
ACRS News
Stories mentioning ACRS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1,996 | 1,295 | 3,299 | 1,777 | 1,455 | 9,210 | 4,346 | 2,766 |
| Cost of Goods Sold | 395.00 | 532.00 | 538.00 | 515.00 | 506.00 | 705.00 | 654.00 | 624.00 |
| Gross Profit | 1,601 | 763.00 | 2,761 | 1,262 | 949.00 | 8,505 | 3,692 | 2,142 |
| Operating Expenses | ||||||||
| Research & Development | 15,657 | 16,584 | 13,028 | 11,449 | 11,584 | 9,026 | 5,956 | 8,759 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (22,192) | (22,734) | (17,149) | (18,408) | (18,084) | (99,676) | (10,471) | (12,854) |
| Interest Income | 1,514 | 1,634 | 1,819 | 2,018 | 2,166 | 2,104 | 1,991 | 1,868 |
| Interest Expense | ||||||||
| Other Expense | 1,868 | |||||||
| Pretax Income | (19,795) | (14,614) | (15,429) | (15,085) | (96,552) | (7,586) | (10,986) | |
| Tax Provision | ||||||||
| Net Income (Loss) | (19,824) | (19,795) | (14,614) | (15,429) | (15,085) | (96,552) | (7,586) | (10,986) |
| Earnings Per Share (Basic) | (0.15) | (0.16) | (0.12) | (0.13) | (0.12) | (1.25) | (0.11) | (0.15) |
| Earnings Per Share (Diluted) | (0.15) | (0.16) | (0.12) | (0.13) | (0.12) | (1.25) | (0.11) | (0.15) |
| Weighted Average Shares Outstanding (Basic) | 128,810 | 122,565 | 122,619 | 122,581 | 122,390 | 77,297 | 71,382 | 71,291 |
| Weighted Average Shares Outstanding (Diluted) | 128,810 | 122,565 | 122,619 | 122,581 | 122,390 | 77,297 | 71,382 | 71,291 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ACRS
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a stock listed on the Nasdaq Stock Market under the ticker symbol ACRS. It last traded at $3.92 (Nov 13, 2026, 4:00 PM ET), down 2.0% on the day. That gives Aclaris Therapeutics a market capitalisation of $655.1M.
Over the past 52 weeks ACRS has traded between $2.25 and $6.60.
Revenue for the quarter ended Mar 31, 2026 was $2.0M; a net loss of $19.8M. Revenue was up 37.2% from $1.5M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $2.0M | -$19.8M | -993.2% |
| Dec 31, 2025 | $1.3M | -$19.8M | -1528.6% |
| Sep 30, 2025 | $3.3M | -$14.6M | -443.0% |
| Jun 30, 2025 | $1.8M | -$15.4M | -868.3% |
From Aclaris Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…